Protalix BioTherapeutics (PLX) Stock Overview
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PLX Community Fair Values
Create NarrativeSee what 58 others think this stock is worth. Follow their fair value or set your own to get alerts.
Protalix BioTherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$0.99 |
| Beta | -0.23 |
| 1 Month Change | 21.57% |
| 3 Month Change | 32.86% |
| 1 Year Change | 61.74% |
| 3 Year Change | 74.91% |
| 5 Year Change | -48.90% |
| Change since IPO | -99.31% |
Recent News & Updates
Recent updates
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
Feb 22
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
Jan 14Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
Dec 10Shareholder Returns
| PLX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.9% | -0.4% | 1.2% |
| 1Y | 61.7% | -9.3% | 19.2% |
Return vs Industry: PLX exceeded the US Biotechs industry which returned -9.3% over the past year.
Return vs Market: PLX exceeded the US Market which returned 19.2% over the past year.
Price Volatility
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PLX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PLX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 213 | Dror Bashan | www.protalix.com |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
Protalix BioTherapeutics, Inc. Fundamentals Summary
| PLX fundamental statistics | |
|---|---|
| Market cap | US$149.10m |
| Earnings (TTM) | US$6.28m |
| Revenue (TTM) | US$61.95m |
Is PLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLX income statement (TTM) | |
|---|---|
| Revenue | US$61.95m |
| Cost of Revenue | US$26.31m |
| Gross Profit | US$35.64m |
| Other Expenses | US$29.36m |
| Earnings | US$6.28m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.079 |
| Gross Margin | 57.53% |
| Net Profit Margin | 10.13% |
| Debt/Equity Ratio | 0% |
How did PLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/18 22:04 |
| End of Day Share Price | 2025/09/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Protalix BioTherapeutics, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Difei Yang | Capstone Investments |
| Raghuram Selvaraju | H.C. Wainwright & Co. |